Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus endocrine therapy as adjuvant treatment for HR-positive, HER2-negative breast cancer
ChiCTR2400080962Phase 4Not yet recruiting
- Sponsor
- Dongguan Donghua Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Dongguan Donghua Hospital. Primary endpoint: Invasive disease-free survival. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400080962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080962.